DE69534250D1 - Polynukleotidimpfstoff gegen tbc - Google Patents

Polynukleotidimpfstoff gegen tbc

Info

Publication number
DE69534250D1
DE69534250D1 DE69534250T DE69534250T DE69534250D1 DE 69534250 D1 DE69534250 D1 DE 69534250D1 DE 69534250 T DE69534250 T DE 69534250T DE 69534250 T DE69534250 T DE 69534250T DE 69534250 D1 DE69534250 D1 DE 69534250D1
Authority
DE
Germany
Prior art keywords
dna
mice
vaccinated mice
response
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69534250T
Other languages
English (en)
Other versions
DE69534250T2 (de
Inventor
Margaret A Liu
Donna Montgomery
Jeffrey Ulmer
Jean Content
Kris Huygen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Merck and Co Inc
Original Assignee
Innogenetics NV SA
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA, Merck and Co Inc filed Critical Innogenetics NV SA
Publication of DE69534250D1 publication Critical patent/DE69534250D1/de
Application granted granted Critical
Publication of DE69534250T2 publication Critical patent/DE69534250T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
DE69534250T 1994-11-14 1995-11-13 Polynukleotidimpfstoff gegen tbc Expired - Fee Related DE69534250T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US338992 1994-11-14
US08/338,992 US5736524A (en) 1994-11-14 1994-11-14 Polynucleotide tuberculosis vaccine
PCT/US1995/014899 WO1996015241A2 (en) 1994-11-14 1995-11-13 A polynucleotide tuberculosis vaccine

Publications (2)

Publication Number Publication Date
DE69534250D1 true DE69534250D1 (de) 2005-07-07
DE69534250T2 DE69534250T2 (de) 2006-05-04

Family

ID=23326996

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534250T Expired - Fee Related DE69534250T2 (de) 1994-11-14 1995-11-13 Polynukleotidimpfstoff gegen tbc

Country Status (23)

Country Link
US (2) US5736524A (de)
EP (1) EP0792358B1 (de)
JP (1) JP3881014B2 (de)
KR (1) KR970707281A (de)
CN (1) CN1171814A (de)
AT (1) ATE296882T1 (de)
AU (1) AU715067B2 (de)
CZ (1) CZ289383B6 (de)
DE (1) DE69534250T2 (de)
DK (1) DK0792358T3 (de)
ES (1) ES2242193T3 (de)
FI (1) FI972034A (de)
HU (1) HU222369B1 (de)
IL (1) IL115883A0 (de)
MX (1) MX9703606A (de)
NO (1) NO972196L (de)
NZ (1) NZ296477A (de)
PL (1) PL184839B1 (de)
PT (1) PT792358E (de)
RU (1) RU2186109C2 (de)
SK (1) SK283254B6 (de)
WO (1) WO1996015241A2 (de)
ZA (1) ZA959608B (de)

Families Citing this family (314)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US20020165183A1 (en) * 1999-11-29 2002-11-07 Hans Herweijer Methods for genetic immunization
US20070021364A1 (en) * 1995-12-13 2007-01-25 Hans Herweijer Methods for genetic immunization
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751228B1 (fr) * 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
EP0935659A1 (de) * 1996-09-17 1999-08-18 Chiron Corporation Zusammensetzungen und verfahren zur behandlung intrazellulärer erkrankungen
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
AU6148798A (en) * 1997-02-07 1998-08-26 Vanderbilt University Synthetic genes for recombinant mycobacterium proteins
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
JP2002511396A (ja) * 1998-04-14 2002-04-16 メルク エンド カムパニー インコーポレーテッド ポリヌクレオチド製剤の無針投与
BR9915055A (pt) * 1998-11-04 2001-08-07 Isis Innovation Teste diagnóstico de tuberculose
US8197461B1 (en) 1998-12-04 2012-06-12 Durect Corporation Controlled release system for delivering therapeutic agents into the inner ear
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
AU3593200A (en) 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
EP2368575B1 (de) * 1999-04-08 2014-10-01 Intercell USA, Inc. Trockenformulierung für transkutane immunisierung
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
EP1194449B1 (de) * 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitoren des memapsin 2 und ihre verwendung
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
EP2278022A3 (de) * 1999-11-01 2011-05-18 Novartis Vaccines and Diagnostics, Inc. Expressionsvektoren, Transfektionssysteme und Verfahren zu deren Verwendung
EP1230268B1 (de) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroklitische analoga von klasse-i epitopen
EP1244687A4 (de) * 1999-12-22 2005-06-15 Univ Ohio State Res Found Schutzma nahmen gegen die tödliche infektion durch i bacillus anthracis
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
AU2001231245A1 (en) 2000-01-31 2001-08-07 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
IL151345A0 (en) * 2000-02-23 2003-04-10 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20030130217A1 (en) * 2000-02-23 2003-07-10 Eyal Raz Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
WO2001082964A1 (en) * 2000-04-28 2001-11-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
US6590087B1 (en) * 2000-05-25 2003-07-08 Johns Hopkins University whmD, an essential cell division gene from mycobacteria
US7288261B2 (en) * 2000-07-10 2007-10-30 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
ES2323407T3 (es) 2000-07-12 2009-07-15 Agensys, Inc. Nuevo antigeno tumoral util en el diagnostico y terapia del cancer de vejiga, ovario, pulmon y riñon.
CA2420990C (en) 2000-08-28 2010-08-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
EP1455816A4 (de) 2000-10-19 2007-03-28 Epimmune Inc Hla-klasse-i- und -ii-bindende peptide und deren verwendung
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
PT1372708E (pt) * 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
JP2004532213A (ja) * 2001-04-06 2004-10-21 ザ ユニヴァーシティ オヴ シカゴ Ｅｇｒ−１プロモーター活性の化学療法誘導
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7013940B2 (en) * 2001-04-19 2006-03-21 Michelin Recherche Et Technique S.A. Device for attenuating cavity noise in a tire and wheel
WO2002095002A2 (en) 2001-05-22 2002-11-28 University Of Chicago N4 virion single-stranded dna dependent rna polymerase
US7604955B2 (en) * 2001-08-13 2009-10-20 Swey-Shen Alex Chen Immunoglobulin E vaccines and methods of use thereof
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
AU2002348417B9 (en) 2001-10-26 2010-02-04 Baylor College Of Medicine A composition and method to alter lean body mass and bone properties in a subject
EP1465654B1 (de) 2001-12-11 2015-02-25 Inovio Pharmaceuticals, Inc. Durch plasmid übertragene supplementierung zur behandlung chronisch kranker patienten
IL162844A0 (en) * 2002-01-18 2005-11-20 Inovio As Use of an expression vector for preparing pharmaceutical compositions
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20030199012A1 (en) * 2002-02-01 2003-10-23 Ho John L. Compositions and methods for treatment of infectious and inflammatory diseases
US20050267025A1 (en) * 2002-02-01 2005-12-01 Ho John L Compositions and methods for treatment of infectious and inflammatory diseases
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP3415625A1 (de) 2002-02-01 2018-12-19 Life Technologies Corporation Doppelsträngige oligonukleotide
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
EP2258712A3 (de) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
WO2003078595A2 (en) * 2002-03-15 2003-09-25 Astral, Inc. Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
US7078037B2 (en) * 2002-04-19 2006-07-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
US20060094006A1 (en) * 2002-05-01 2006-05-04 Genoveffa Franchini Immunotherapy regimens in hiv-infected patients
NZ537579A (en) 2002-06-10 2006-10-27 Vaccinex Inc C35 peptide epitopes and their analogs
WO2004006837A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) * 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
JP4570565B2 (ja) 2002-07-15 2010-10-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ペリプラズム発現によるコンビナトリアルタンパク質ライブラリーのスクリーニング
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
EP2269618A1 (de) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Ein onkolytisches Vaccinia-Virus zur Verwendung in Kombination mit Chemotherapie zur Behandlung von Krebs
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
WO2004050828A2 (en) 2002-11-27 2004-06-17 Agensys, Inc. Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
WO2004072263A2 (en) 2003-02-10 2004-08-26 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
US7262027B2 (en) * 2003-03-14 2007-08-28 Medical College Of Ohio Polypeptide and DNA immunization against Coccidioides spp. infections
AU2004225480A1 (en) * 2003-03-26 2004-10-14 Multicell Immunotherapeutics, Inc. Selected RNA motifs to include cell death and/or apoptosis
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
US20070037151A1 (en) * 2003-04-28 2007-02-15 Babe Lilia M Cd4+ human papillomavirus (hpv) epitopes
NZ578591A (en) 2003-05-30 2011-01-28 Agensys Inc Prostate stem cell antigen (PSCA) variants and subsequences thereof, namely SEQ ID NO: 6554
US20060240039A1 (en) * 2003-06-13 2006-10-26 Isis Innovation Limited Vaccines
EP2336768A1 (de) 2003-07-09 2011-06-22 Life Technologies Corporation Verfahren zum testen einer Protein-Protein-Wechselwirkung
US20070224615A1 (en) * 2003-07-09 2007-09-27 Invitrogen Corporation Methods for assaying protein-protein interactions
WO2005025497A2 (en) * 2003-09-05 2005-03-24 Genencor International, Inc. Hpv cd8+ t-cell epitopes
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
AU2005212479B2 (en) * 2004-02-11 2009-09-10 Msd Italia S.R.L. Carcinoembryonic antigen fusion proteins and uses thereof
EP1735435A1 (de) * 2004-03-18 2006-12-27 Fred Hutchinson Cancer Research Center Verfahren und zusammensetzungen unter beteiligung von s-ship-promotorbereichen
NZ551627A (en) 2004-05-28 2010-02-26 Agensys Inc Antibodies and related molecules that bind to PSCA proteins
US20090221440A1 (en) * 2004-07-12 2009-09-03 Board Of Regents, The University Of Texas System Methods and compositions related to identifying protein-protein interactions
WO2006135382A2 (en) 2004-08-04 2006-12-21 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
NZ581306A (en) 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
AU2005312062B2 (en) * 2004-12-01 2011-11-17 Aeras Global Tb Vaccine Foundation Electroporation of Mycobacterium and overexpression of antigens in Mycobacteria
EP1851343A2 (de) * 2005-02-11 2007-11-07 Merck and Co., Inc. Adenovirus serotyp 26-vektoren, nukleinsäure und auf diese weise erzeugte viren
PL2325305T3 (pl) 2005-02-25 2014-07-31 Oncotherapy Science Inc Szczepionki peptydowe na nowotwory płuc z ekspresją polipeptydów TTK, URLC10 lub KOC1
SI2289533T1 (sl) 2005-02-28 2013-11-29 Oncotherapy Science, Inc. Epitopni peptidi, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja in cepiva, ki vsebujejo te peptide
EP2444099A1 (de) 2005-03-31 2012-04-25 Agensys, Inc. An 161P2F10B-Proteine bindende Antikörper und zugehörige Moleküle
SI2298815T1 (sl) 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
HUE027330T2 (en) 2005-07-27 2016-09-28 Oncotherapy Science Inc The TOM34 gene for colon cancer
AU2006279896A1 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating Alzheimer's disease
KR20090004839A (ko) * 2005-09-07 2009-01-12 제네렉스, 인코포레이티드 Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US7919258B2 (en) * 2005-10-07 2011-04-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Rapid tuberculosis detection method
WO2008019162A2 (en) 2006-01-18 2008-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP1994409A2 (de) 2006-03-14 2008-11-26 Oregon Health and Science University Verfahren zum hervorrufen einer immunantwort auf tuberkulose
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
EP2069791B1 (de) 2006-07-27 2012-01-25 University of Maryland, Baltimore Zellulärer rezeptor für antiproliferativen faktor
EP2064229B1 (de) 2006-09-15 2015-08-12 Ottawa Hospital Research Institute Onkolytisches rhabdovirus
RU2469044C2 (ru) 2006-10-17 2012-12-10 Онкотерапи Сайенс, Инк. Пептидные вакцины против рака с экспрессией полипептидов mphosph1 или depdc1
MX2009004221A (es) 2006-10-20 2009-09-10 Univ Arizona State Cianobacterias modificadas.
EP2102239B1 (de) 2006-11-30 2012-04-25 Research Development Foundation Verbesserte immunglobulin-bibliotheken
TWI596109B (zh) 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
TW201425333A (zh) 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
DK2155789T3 (da) 2007-05-01 2013-10-21 Res Dev Foundation Immunoglobulin-Fc-biblioteker
AU2008287195A1 (en) * 2007-07-06 2009-02-19 Emergent Product Development Seattle, Llc Binding peptides having a C-terminally disposed specific binding domain
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US20100310640A1 (en) 2007-11-01 2010-12-09 Knutson Keith L Hla-dr binding peptides and their uses
JP5677703B2 (ja) 2008-01-10 2015-02-25 リサーチ ディベロップメント ファウンデーション Ｅｈｒｌｉｃｈｉａｃｈａｆｆｅｅｎｓｉｓにのためのワクチンおよび診断
CA2739944A1 (en) * 2008-01-23 2009-07-30 Rigshospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
DK2245464T3 (en) 2008-01-25 2017-02-20 Multivir Inc P53 BIOMARKETS
MX2010010165A (es) 2008-03-17 2010-11-25 Scripps Research Inst Procedimientos quimicos y geneticos combinados para generacion de celulas madre pluripotentes inducidas.
WO2009117134A2 (en) * 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
WO2009126944A1 (en) * 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
KR101871192B1 (ko) 2008-06-04 2018-06-27 후지필름 셀룰러 다이내믹스, 인코포레이티드 비-바이러스 접근법을 사용한 ｉＰＳ 세포의 생산 방법
AU2009273128A1 (en) * 2008-07-25 2010-03-11 All India Institute Of Medical Science Constructing a DNA chimera for vaccine development against Leishmaniasis and tuberculosis
EP2331696A1 (de) 2008-08-12 2011-06-15 Cellular Dynamics International, Inc. Verfahren zur herstellung von ips-zellen
EP2328603A4 (de) 2008-08-18 2013-01-02 Univ Maryland Apf-derivate und verwendungsverfahren
US8512944B2 (en) 2008-08-27 2013-08-20 Oncotherapy Science, Inc. PRMT1 for target genes of cancer therapy and diagnosis
AU2009302582A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins
JP2012506858A (ja) * 2008-10-23 2012-03-22 インターベット インターナショナル ベー． フェー． Ｌａｗｓｏｎｉａｉｎｔｒａｃｅｌｌｕｌａｒｉｓワクチン
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
EP3312269A1 (de) 2008-12-17 2018-04-25 The Scripps Research Institute Erzeugung und erhaltung von stammzellen
EP2379720B1 (de) 2009-01-20 2016-08-17 Alona Zilberberg Durch den promoter mir-21 angetriebene gezielte krebstherapie
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
PT2408913T (pt) 2009-03-18 2017-03-07 Oncotherapy Science Inc Péptidos neil3 e vacinas que incluem os mesmos
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Preparations and method for Protein A (SPA) variants
DK3061766T3 (da) 2009-04-28 2020-03-16 Univ Vanderbilt Sammensætninger og fremgangsmåder til behandlingen af sygdomme der involverer epitelcelleapoptose
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
CN102459575A (zh) 2009-06-05 2012-05-16 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
CA2772298A1 (en) 2009-08-26 2011-03-03 Research Development Foundation Methods for creating antibody libraries
CN107303302A (zh) 2009-09-14 2017-10-31 希拉金股份有限公司 溶瘤牛痘病毒组合癌症疗法
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
US9265822B2 (en) * 2009-09-30 2016-02-23 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
CN105861446B (zh) 2009-10-16 2021-10-01 斯克里普斯研究所 多能细胞的诱导
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
MX337062B (es) 2009-12-10 2016-02-11 Ottawa Hospital Res Inst Rabdovirus oncolítico.
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
US10080799B2 (en) 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
EP3028699B1 (de) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf-mutationen für resistenz gegen braf-inhibitoren
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
ES2631458T3 (es) 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
SG10201501857YA (en) 2010-03-11 2015-05-28 Oncotherapy Science Inc Hjurp Peptides And Vaccines Including The Same
EP2553086B1 (de) 2010-03-31 2017-04-19 The Scripps Research Institute Umprogrammierung von zellen
TW201627003A (zh) 2010-04-02 2016-08-01 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
WO2011126976A1 (en) 2010-04-07 2011-10-13 Vanderbilt University Reovirus vaccines and methods of use therefor
US8785385B2 (en) 2010-04-19 2014-07-22 Research Development Foundation RTEF-1 variants and uses thereof
WO2011156588A1 (en) 2010-06-09 2011-12-15 Dana-Farber Cancer Institute, Inc. A mek 1 mutation conferring resistance to raf and mek inhibitors
ES2685171T3 (es) 2010-06-14 2018-10-05 The Scripps Research Institute Reprogramación de células a un nuevo destino
EP2582793B1 (de) 2010-06-15 2017-09-06 Cellular Dynamics International, Inc. Kompendium aus fertig gebauten stammzellmodellen zur abfrage biologischer reaktionen
ES2670842T3 (es) 2010-06-15 2018-06-01 Cellular Dynamics International, Inc. Generación de células madre pluripotentes inducidas a partir de pequeños volúmenes de sangre periférica
EP2588120B1 (de) 2010-07-02 2017-11-15 The University of Chicago Zusammensetzungen und verfahren bezüglich protein-a (spa)-varianten
EP2591106A1 (de) 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna und ihre diagnostischen und therapeutischen verwendungen für mit melanomen assoziierte erkrankungen oder leiden oder für mit dem aktivierten braf-pfad assoziierte erkrankungen oder leiden
JP5897002B2 (ja) 2010-07-07 2016-04-13 セルラー ダイナミクス インターナショナル， インコーポレイテッド プログラミングによる内皮細胞の産生
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
EP2618829B1 (de) 2010-09-22 2019-05-01 The Regents of the University of Colorado, a body corporate Smad7 zur behandlung von oraler mukositis oder psoriasis
CN103282048B (zh) 2010-10-01 2017-05-17 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
US20130267029A1 (en) 2010-10-01 2013-10-10 Fundacion Centro Nacional de Ivestigaciones Oncologicas, Carlos Manipulation of stem cell function by p53 isoforms
KR102160721B1 (ko) 2010-12-22 2020-09-29 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
KR101942237B1 (ko) 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
EP2474617A1 (de) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR zur Behandlung von Neoangiogenese
RU2539035C2 (ru) * 2011-01-13 2015-01-10 Амир Закиевич Максютов Профилактическая или терапевтическая полиэпитопная противотуберкулезная вакцинная конструкция, обеспечивающая индукцию клеточного иммунного ответа cd4+ или cd8+ т-лимфоцитов
WO2012109133A1 (en) 2011-02-07 2012-08-16 Research Development Foundation Engineered immunoglobulin fc polypeptides
US9574179B2 (en) 2011-02-08 2017-02-21 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
CN103687611A (zh) 2011-03-11 2014-03-26 阿德瓦希斯公司 基于李斯特菌属的佐剂
EP2694534B1 (de) 2011-04-08 2018-06-20 Evaxion Biotech ApS Proteine und nukleinsäuren zur verwendung für impstoffe gegen staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9822379B2 (en) 2011-05-19 2017-11-21 Fundación Pública Andaluza Progreso Y Salud Highly inducible dual-promoter lentiviral TET-ON system
EP2718427B1 (de) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Zusammensetzungen zur behandlung von glioblastomen
EP2732029B1 (de) 2011-07-11 2019-01-16 FUJIFILM Cellular Dynamics, Inc. Verfahren zur zellprogrammierung und genommanipulation
EP2738255B1 (de) 2011-07-29 2016-11-23 Tokushima University Peptid aus erap1 und seine verwendung
RU2612905C2 (ru) 2011-08-12 2017-03-13 Онкотерапи Сайенс, Инк. Пептиды mphosph1 и вакцины, включающие их
AU2012296576B2 (en) 2011-08-15 2017-09-07 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
JP2013046596A (ja) * 2011-08-29 2013-03-07 Alpha-Nano-Medica Co Ltd 新規な複合体、それを含有する医薬及び癌の治療方法
EP2766388A1 (de) 2011-10-12 2014-08-20 Møller, Niels Iversen Peptide aus campylobacter jejuni und ihre verwendung bei der impfung
EP3296317B1 (de) 2011-10-28 2019-12-11 OncoTherapy Science, Inc. Topk-peptide und impfstoffe damit
ES2688619T3 (es) 2011-12-22 2018-11-05 Interna Technologies B.V. MiARN para tratar el cáncer de cabeza y de cuello
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
EP2844275B1 (de) 2012-04-26 2020-05-13 University of Chicago Staphylokokken-coagulase-antigene und verfahren zu deren verwendung
CA2910320A1 (en) 2012-04-26 2013-10-31 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
JP6259983B2 (ja) 2012-07-10 2018-01-17 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＫＩＦ２０Ａエピトープペプチドおよびこれを含有するワクチン
WO2014010232A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Ly6k epitope peptides for th1 cells and vaccines containing the same
US10092634B2 (en) 2012-09-11 2018-10-09 Oncotherapy Science, Inc. UBE2T peptides and vaccines containing the same
WO2014065945A1 (en) 2012-10-23 2014-05-01 The Board Of Regents Of The University Of Texas System Antibodies with engineered igg fc domains
EP3800256A1 (de) 2012-11-06 2021-04-07 InteRNA Technologies B.V. Kombination zur therapeutischen verwendung bei krankheiten oder zuständen im zusammenhang mit melanomen oder bei krankheiten oder zuständen im zusammenhang mit dem aktivierten b-raf-signalweg
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
EP2958990B1 (de) 2013-02-20 2019-10-16 Regeneron Pharmaceuticals, Inc. Genetische modifikation von ratten
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
US20140242595A1 (en) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
EP2961386B1 (de) 2013-02-28 2019-07-10 The General Hospital Corporation Mirna-profilierungszusammensetzungen und verfahren zur verwendung
US10456448B2 (en) 2013-03-08 2019-10-29 The Regents Of The University Of Colorado, A Body Corporate PTD-SMAD7 therapeutics
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
WO2014140301A1 (en) * 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
WO2014153636A1 (en) 2013-03-27 2014-10-02 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
CN105636614A (zh) 2013-09-09 2016-06-01 菲格内有限责任公司 用于软骨细胞或软骨型细胞再生的基因治疗
US20170002064A1 (en) 2013-11-08 2017-01-05 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
WO2015070050A1 (en) 2013-11-08 2015-05-14 Baylor Research Institute Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure
EP3077820A1 (de) 2013-12-03 2016-10-12 Evaxion Biotech ApS Proteine und nukleinsäuren zur verwendung für impfstoffe gegen staphylococcus aureus
KR102448454B1 (ko) 2014-01-29 2022-09-28 다나-파버 캔서 인스티튜트 인크. Muc1-c/세포외 도메인 (muc1-c/ecd)에 대한 항체
EP3105332A4 (de) 2014-02-14 2018-01-10 University of Utah Research Foundation Verfahren und zusammensetzungen zur hemmung von frühgeborenen-retinopathie
CA2940765A1 (en) 2014-02-25 2015-09-03 Research Development Foundation Sty peptides for inhibition of angiogenesis
US11268069B2 (en) 2014-03-04 2022-03-08 Fate Therapeutics, Inc. Reprogramming methods and cell culture platforms
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
CN106715461B (zh) 2014-08-04 2020-11-24 肿瘤疗法科学股份有限公司 Koc1衍生的肽和包含它们的疫苗
BR112017002212A2 (pt) 2014-08-04 2017-11-21 Oncotherapy Science Inc peptídeo derivado de cdca1 e vacina contendo o mesmo
JP6700513B2 (ja) 2014-08-04 2020-05-27 オンコセラピー・サイエンス株式会社 Ｕｒｌｃ１０由来ペプチドおよびそれを含むワクチン
EP3194623B1 (de) 2014-08-12 2022-01-05 Wayne State University Systeme und verfahren zur erkennung von stress von stammzellen und verwendungen davon
EP3218002B1 (de) 2014-11-13 2020-08-19 Evaxion Biotech ApS Aus acinetobacter baumannii abgeleitete peptide und deren verwendung bei der impfung
CA2972635A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
EP3485907B1 (de) 2015-01-12 2023-06-28 Evaxion Biotech ApS Behandlung und prophylaxe von k.-pneumoniae-infektionen
US20180002656A1 (en) 2015-01-28 2018-01-04 Sabic Global Technologies B.V. Methods and compositions for high-efficiency production of biofuel and/or biomass
CA2976236A1 (en) 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
US11421229B2 (en) 2015-02-20 2022-08-23 Baylor College Of Medicine p63 inactivation for the treatment of heart failure
ES2959642T3 (es) 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP3317295B1 (de) 2015-07-04 2022-05-18 Evaxion Biotech A/S Proteine und nukleinsäuren, die in impfstoffen gegen pseudomonas aeruginosa nützlich sind
WO2017040380A2 (en) 2015-08-28 2017-03-09 Research Development Foundation Engineered antibody fc variants
JP7002446B2 (ja) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
JP6873482B2 (ja) 2015-10-08 2021-05-19 オンコセラピー・サイエンス株式会社 Ｆｏｘｍ１由来ペプチドおよびそれを含むワクチン
US11441126B2 (en) 2015-10-16 2022-09-13 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
AU2016342179B2 (en) 2015-10-20 2022-08-18 FUJIFILM Cellular Dynamics, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
CN108463548B (zh) 2015-10-30 2023-04-18 加利福尼亚大学董事会 由干细胞产生t细胞的方法及使用所述t细胞的免疫治疗方法
SI3370733T1 (sl) 2015-11-02 2021-11-30 Board Of Regents The University Of Texas System Postopek za aktivacijo CD40 in blokada imunske nadzorne točke
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
US11814440B2 (en) 2015-11-09 2023-11-14 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
EP3419654B1 (de) 2016-02-22 2022-04-27 Evaxion Biotech A/S In impfstoffen gegen staphylococcus aureus nützliche proteine und nukleinsäuren
EP3436049B1 (de) 2016-03-31 2022-01-12 Baylor Research Institute Angiopoietin-ähnliches protein 8 (angptl8)
WO2017216384A1 (en) 2016-06-17 2017-12-21 Evaxion Biotech Aps Vaccination targeting ichthyophthirius multifiliis
US11091775B2 (en) * 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
WO2017220787A1 (en) 2016-06-24 2017-12-28 Evaxion Biotech Aps Vaccines against aearomonas salmonicida infection
JP7099967B2 (ja) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション 幹細胞由来移植片からの増殖性細胞の排除
WO2018015575A1 (en) 2016-07-22 2018-01-25 Evaxion Biotech Aps Chimeric proteins for inducing immunity towards infection with s. aureus
US9963498B2 (en) 2016-08-18 2018-05-08 Wisconsin Alumni Research Foundation Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
BR112019006910A2 (pt) 2016-10-05 2019-07-02 Fujifilm Cellular Dynamics Inc métodos para diferenciação dirigida de células-tronco pluripotentes para células imunes homozigóticas de hla
JP7248571B2 (ja) 2016-10-05 2023-03-29 フジフィルム セルラー ダイナミクス，インコーポレイテッド ＭｅＣＰ２が破壊された誘導多能性幹細胞からの成熟系列の生成
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
EP3565576A1 (de) 2017-01-05 2019-11-13 Evaxion Biotech ApS Impfstoffe gegen pseudomonas aeruginosa
US20200123501A1 (en) 2017-04-18 2020-04-23 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
WO2019086603A1 (en) 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
US11612618B2 (en) 2017-11-14 2023-03-28 Henry Ford Health System Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury
US20200385758A1 (en) 2018-01-05 2020-12-10 Ottawa Hospital Research Institute Modified vaccinia vectors
WO2019145399A1 (en) 2018-01-24 2019-08-01 Evaxion Biotech Aps Vaccines for prophylaxis of s. aureus infections
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
CA3133899A1 (en) 2018-03-30 2019-10-03 University Of Geneva Micro rna expression constructs and uses thereof
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
KR20210102870A (ko) 2018-08-30 2021-08-20 테나야 테라퓨틱스, 인코포레이티드 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
WO2020069313A2 (en) 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
WO2020083904A1 (en) 2018-10-22 2020-04-30 Evaxion Biotech Aps Vaccines targeting m. catharrhalis
US20220098256A1 (en) 2018-11-30 2022-03-31 Tokushima University Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
EP3931206A1 (de) 2019-02-27 2022-01-05 Evaxion Biotech ApS Impfstoffe gegen h. influenzae
WO2021007515A1 (en) 2019-07-11 2021-01-14 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
CN114555807A (zh) 2019-07-19 2022-05-27 费城儿童医院 包含磷脂酰肌醇蛋白聚糖2结合结构域的嵌合抗原受体
WO2021076930A1 (en) 2019-10-18 2021-04-22 The Regents Of The University Of California Plxdc activators and their use in the treatment of blood vessel disorders
KR102237349B1 (ko) 2019-10-23 2021-04-07 한국과학기술연구원 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021140123A1 (en) 2020-01-06 2021-07-15 Evaxion Biotech Aps Vaccines targeting neisseria gonorrhoeae
AU2021230476A1 (en) 2020-03-02 2022-10-20 Tenaya Therapeutics, Inc. Gene vector control by cardiomyocyte-expressed microRNAs
EP4127148A1 (de) 2020-03-25 2023-02-08 Erasmus University Rotterdam Medical Center Reportersystem zur radionuklidbildgebung
EP4157864A1 (de) 2020-05-27 2023-04-05 Antion Biosciences SA Adaptermoleküle zur umleitung von car-t-zellen zu einem antigen von interesse
CN116033912A (zh) 2020-05-29 2023-04-28 富士胶片细胞动力公司 视网膜色素上皮和感光器双细胞聚集物及其使用方法
IL298254A (en) 2020-05-29 2023-01-01 Fujifilm Cellular Dynamics Inc Double layer of retinal pigment epithelium and photoreceptors and their uses
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
CA3202849A1 (en) 2021-02-09 2022-08-18 University Of Houston System Oncolytic virus for systemic delivery and enhanced anti-tumor activities
US20240122865A1 (en) 2021-02-19 2024-04-18 Pfizer Inc. Methods of Protecting RNA
EP4334437A1 (de) 2021-05-03 2024-03-13 Astellas Institute for Regenerative Medicine Verfahren zur erzeugung reifer hornhautendothelzellen
EP4334435A1 (de) 2021-05-07 2024-03-13 Astellas Institute for Regenerative Medicine Verfahren zur erzeugung reifer hepatozyten
US20220389436A1 (en) 2021-05-26 2022-12-08 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
WO2023280807A1 (en) 2021-07-05 2023-01-12 Evaxion Biotech A/S Vaccines targeting neisseria gonorrhoeae
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
WO2023144779A1 (en) 2022-01-28 2023-08-03 Pfizer Inc. Coronavirus antigen variants
US20230295661A1 (en) 2022-03-16 2023-09-21 University Of Houston System Persistent hsv gene delivery system
GB202205265D0 (en) 2022-04-11 2022-05-25 Mogrify Ltd Cell conversion
GB202206507D0 (en) 2022-05-04 2022-06-15 Antion Biosciences Sa Expression construct
WO2023213393A1 (en) 2022-05-04 2023-11-09 Evaxion Biotech A/S Staphylococcal protein variants and truncates
US20240010742A1 (en) 2022-06-10 2024-01-11 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
WO2024006911A1 (en) 2022-06-29 2024-01-04 FUJIFILM Holdings America Corporation Ipsc-derived astrocytes and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5807830A (en) * 1987-12-30 1998-09-15 Cytoven J.V. Method for treatment of purulent inflammatory diseases
ATE277193T1 (de) * 1989-03-21 2004-10-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
CA2042016C (en) * 1989-09-19 2004-04-06 Jean Content Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
EP0499003A1 (de) * 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptide und Peptide, insbesondere rekombinante Polypeptide und Peptide, dafür kodierende Nukleinsäuren und Verwendung dieser Polypeptide und Peptide in der Tuberkulosediagnose
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
IL108915A0 (en) * 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
WO1997000067A1 (en) * 1995-06-15 1997-01-03 University Of Victoria Innovation And Development Mycobacterium tuberculosis dna sequences encoding immunostimulatory peptides
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections

Also Published As

Publication number Publication date
HUT77028A (hu) 1998-03-02
NO972196L (no) 1997-07-11
CN1171814A (zh) 1998-01-28
CZ289383B6 (cs) 2002-01-16
CZ145197A3 (en) 1997-10-15
FI972034A0 (fi) 1997-05-13
FI972034A (fi) 1997-07-11
EP0792358B1 (de) 2005-06-01
NZ296477A (en) 1999-04-29
MX9703606A (es) 1998-07-31
ZA959608B (en) 1996-05-29
WO1996015241A3 (en) 1996-11-07
SK59797A3 (en) 1998-01-14
ATE296882T1 (de) 2005-06-15
AU715067B2 (en) 2000-01-13
US5736524A (en) 1998-04-07
US6384018B1 (en) 2002-05-07
DK0792358T3 (da) 2005-08-29
WO1996015241A2 (en) 1996-05-23
RU2186109C2 (ru) 2002-07-27
SK283254B6 (sk) 2003-04-01
NO972196D0 (no) 1997-05-13
ES2242193T3 (es) 2005-11-01
DE69534250T2 (de) 2006-05-04
HU222369B1 (hu) 2003-06-28
US20020032162A1 (en) 2002-03-14
PL320091A1 (en) 1997-09-15
AU4110296A (en) 1996-06-06
PT792358E (pt) 2005-09-30
KR970707281A (ko) 1997-12-01
JPH10508753A (ja) 1998-09-02
PL184839B1 (pl) 2002-12-31
EP0792358A2 (de) 1997-09-03
IL115883A0 (en) 1996-01-31
JP3881014B2 (ja) 2007-02-14

Similar Documents

Publication Publication Date Title
ATE296882T1 (de) Polynukleotidimpfstoff gegen tbc
Saxena et al. Pre-existing immunity against vaccine vectors–friend or foe?
Reed et al. Prospects for a better vaccine against tuberculosis
Bastos et al. Recombinant mycobacterium bovis BCG
Kamath et al. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis
Dietrich et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity
Kita et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model
Branger et al. Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge
Jain et al. Evaluation of immunogenicity and protective efficacy of a plasmid DNA vaccine encoding ribosomal protein L9 of Brucella abortus in BALB/c mice
Wedlock et al. Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone
Triccas et al. Comparative affects of plasmid‐encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis
Bumann Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4+-T-cell responses
Golshani et al. Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against Brucella infection using Omp2b in BALB/c Mice
Young et al. Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid‐encoded cytokines against Mycobacterium bovis
Huygen DNA vaccines against mycobacterial diseases
Ohara et al. Protective responses against experimental Mycobacterium leprae infection in mice induced by recombinant Bacillus Calmette-Guerin over-producing three putative protective antigen candidates
Vordermeier et al. Development of cattle TB vaccines in the UK
Baloglu et al. Humoral immune response of BALB/c mice to a vaccinia virus recombinant expressing Brucella abortus GroEL does not correlate with protection against a B. abortus challenge
CA2205175A1 (en) A polynucleotide tuberculosis vaccine
Hernandez-Pando et al. Recombinant BCG vaccine candidates
Dietrich et al. Novel vaccination strategies based on recombinant Mycobacterium bovis BCG
Decrausaz et al. Intravaginal live attenuated Salmonella increases local antitumor vaccine-specific CD8+ T cells
CN101428143B (zh) 携带结核基因的减毒细菌载体结核疫苗及制备方法和应用
Lee et al. Evaluation of phoP and rpoS mutants of Salmonella enterica serovar Typhi as attenuated typhoid vaccine candidates: virulence and protective immune responses in intranasally immunized mice
Moradi et al. A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee